TORG
Cryptocurrencies seem to be the flavour of the season as increasingly more people around the world are embracing them; sometimes even abandoning their traditional avenues like Equity, Gold, etc. Though the concept of crypto (as they are informally called) investment seems novel, the first cryptocurrency came into the market more than a decade back. The reliable supply, decentralised control, swift success, and exorbitant returns given by cryptocurrencies have now allayed all fears of them being a ‘fad’ or even a ‘sham’. Today, you have many different options of cryptocurrencies trading on different real-time online platforms.
Though, as the cryptocurrencies do not have any underlying asset to base your buying or selling decision upon (for example – Google shares move on the performance of the Google companies), all the cryptocurrencies on the face look similar. But, one cryptocurrency, recently launched, is destined to change all that, and is already making waves around the world as people are lapping it up in droves.
TORG is the world’s first sustainability driven, completely decentralized, and utility-focused cryptocurrency, aimed at global human development. If it sounds confusing, it’s because it’s such a new concept. As the world’s first utilimeme, it combines the power of meme-driven popularity with the sustainability that comes with a focus on global utility.
Launched recently on 20th July 2021, TORG has already reached the maximum supply of 777 billion and its current circulating supply is 100%. TORG is secured as an ERC-20 token on the Ethereum blockchain. It is not open to pausing, minting, and mining. Being extremely secure and stable, TORG’s smart contract is audited by the best in the industry blockchain security and infrastructure leader Certik.
TORG started trading from 20th July 2021 on world’s leading Global Exchanges, namely Uniswap , BitMart , CoinTiger , ProBit , CoinsBit Global , CoinsBit India , WhiteBit , HotBit.io , LA Token , IndoEx International , Bilaxy , etc. It is expanding its reach rapidly and is expected to be available on many trading platforms, big & small, shortly. Since the launch, different pairs of TORG have been added by the centralized exchanges, including TORG/USDT, TORG/BTC, and TORG/ETH .
TORG – It is different, but is it better?
What makes TORG better than other cryptocurrencies is the same thing that makes the world a better place to live in, i.e. focus on sustainability. TORG is not just any regular cryptocurrency. It is the world’s first cryptocurrency that has sustainability & utility as its underlying core assets. It aims to increase commercial & business activities, generate growth & employment opportunities for the world’s youth, develop eco-friendly infrastructure around the world, push the population to adopt green initiatives, and alleviate the economic constraints facing the world’s marginalized demographic sections.
About TORG
TORG Foundation is the force behind this intuitive & innovative cryptocurrency that aims to disrupt the crypto market forever. With the mission & vision of helping the society keep its carbon footprint to the minimum while increasing the economic activities both in developing & developed countries for the holistic development of mankind, the foundation keeps the interests of humanity and mankind at the core of all its decisions.
To maintain the full transparency of transactions, TORG is completely decentralised, and the foundation does not & cannot decide or predict its price movements.
It’s #TORGTime.
For more information and updates, visit www.torg.to or follow TORG on Twitter , Telegram , Facebook , and Medium .
Disclaimer: The information available on this article is for educational purposes only and not an offer, solicitation of an offer, or advice to buy or sell securities, investment or tax advice. Purchasing cryptocurrencies comes with a number of risks. All Forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from the statements made here. The data and non-TORG names are for informational and identification purposes only.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210820005103/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom